Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • 8 hours ago

Collegium Provides 2026 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update.

GlobeNewsWire • Jan 8, 2026

Collegium Announces the Closing of $980 Million Syndicated Credit Facility

STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.

GlobeNewsWire • Dec 30, 2025

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Dec 22, 2025

Best Value Stocks to Buy for Dec. 18

KE, COLL and JRVR made it to the Zacks Rank #1 (Strong Buy) value stocks list on Dec. 18, 2025.

Zacks Investment Research • Dec 18, 2025

Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run?

Collegium Pharmaceutical (COLL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Dec 4, 2025

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Dec 4, 2025

Why 2025 is a Dynamic and Transformative Year for Collegium

COLL's bold buybacks, board refresh and expanding ADHD push highlight a year of strategic moves and rising momentum.

Zacks Investment Research • Nov 21, 2025

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Nov 18, 2025

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare Conference Presentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m.

GlobeNewsWire • Nov 12, 2025